Skip to content
Guides

GLP-1 Side Effects: What to Expect and How to Manage Them

The common, the rare, and the ones worth watching — plus practical strategies that reduce nausea and GI upset.

8 min readWritten and fact-checked against the sources below

Read this first

Educational, not medical advice. If you have concerning symptoms, contact your clinician or seek urgent care. Compounded GLP-1s are not FDA-approved, and since the 2025 shortage delistings they can only be dispensed in narrow, patient-specific circumstances.

The most common side effects are also the most manageable — and the rarest ones are the ones you need to know to catch. Here's the realistic map.

What are the most common GLP-1 side effects?

  • Nausea — the #1 complaint; usually worst in the first few weeks and with dose increases.
  • Changes in appetite, bloating, constipation or diarrhea.
  • Injection-site reactions — redness or irritation where you inject.
  • These tend to ease as your body adjusts, and going up doses slowly helps.

What are the rarer but serious GLP-1 risks?

  • Pancreatitis — severe, persistent abdominal pain; rare but serious.
  • Gallbladder problems (gallstones, cholecystitis) — increased risk in trials.
  • Hypoglycemia — mainly a risk if combined with insulin or sulfonylureas.
  • Kidney stress — dehydration from vomiting/diarrhea can affect kidneys.

What is the boxed warning on GLP-1s?

Wegovy and Zepbound both carry a boxed warning — the FDA's most serious label warning — for thyroid C-cell tumors. In rodent studies these drugs caused thyroid C-cell tumors; whether they do so in humans is not known.

  • They are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC).
  • They are contraindicated if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • The labels also direct clinicians to monitor for new or worsening depression, suicidal thoughts, or unusual mood changes.
  • Tirzepatide is not recommended in people with severe gastroparesis.

This is exactly the kind of screening a prescribing clinician is responsible for, and it is a reason the intake questions matter. Read the full prescribing information linked in the sources below.

When should you call a clinician about GLP-1 side effects?

  • Severe abdominal pain, especially with vomiting
  • Signs of a severe allergic reaction (swelling, trouble breathing)
  • Persistent vomiting or inability to keep fluids down
  • Rapid heartbeat or chest pain

How do you reduce GLP-1 nausea and GI side effects?

  • Eat smaller, lower-fat meals; fat slows stomach emptying further.
  • Stay hydrated, especially if you have any GI upset.
  • Go up doses slowly rather than jumping.
  • Don't combine with other things that upset your stomach without checking with your clinician.

Bottom line

Most side effects are common, expected, and manageable. A few are rare but serious and need prompt attention. This is general information — your clinician knows your history and is the right person for your specific risks.

Want this handled for you?

LunaRx — clinician-led GLP-1 care with a plan to come off

LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.

Start the 2-minute eligibility checkIndependent site · by LunaRx · not medical advice

Sources

Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.

  1. 1.
    WEGOVY (semaglutide) injection — full prescribing information

    DailyMed, U.S. National Library of Medicine · 2026

    Boxed warning for thyroid C-cell tumors, MTC/MEN 2 contraindications, and the labeled adverse-reaction profile.

  2. 2.
    ZEPBOUND (tirzepatide) injection — full prescribing information

    DailyMed, U.S. National Library of Medicine · 2026

    Boxed warning for thyroid C-cell tumors, MTC/MEN 2 contraindications, and gastroparesis guidance.

  3. 3.
    STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Wilding JPH, et al. · New England Journal of Medicine · 2021

    Mean weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo at 68 weeks.

  4. 4.
    SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity

    Jastreboff AM, et al. · New England Journal of Medicine · 2022

    Mean weight change of −20.9% on tirzepatide 15 mg at 72 weeks, in 2,539 adults without diabetes.

Get the weekly research update

New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.

Unsubscribe anytime. Read our privacy policy.

Related in Guides